SEC Form 4 · accession 0001445064-15-000032
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President & CEO · Director
Period of report
Feb 1, 2015
Accepted (ET)
Feb 3, 2015 · 5:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 1, 2015 | F | 3,440 | $105.99 | D | 157,197 | D | |
| Ordinary Shares | Feb 2, 2015 | M | 17,904 | $37.85 | A | 175,101 | D | |
| Ordinary SharesF2 | Feb 2, 2015 | S | 6,625 | $105.51 | D | 168,476 | D | |
| Ordinary SharesF3 | Feb 2, 2015 | S | 4,200 | $106.31 | D | 164,276 | D | |
| Ordinary SharesF4 | Feb 2, 2015 | S | 1,100 | $107.17 | D | 163,176 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Options (Right to Buy)F5 | $37.85 | Feb 2, 2015 | M | 17,904 | A | Feb 1, 2013 | Jan 31, 2022 | Ordinary Shares | 17,904 | 17,904 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 4, 2014.
- F2This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $104.90 to $105.87, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc, or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (4) to this Form 4.
- F3This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $105.91 to $106.89, inclusive.
- F4This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $106.92 to $107.50, inclusive.
- F5The options representing rights to purchase 71,616 ordinary shares became exercisable in four equal installments beginning on February 1, 2013, which is the first anniversary from the date of the grant.